Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

Benzinga Newsdesk www.benzinga.com Positive 61.1%

Neg 0% Neu 0% Pos 61.1%

Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.